망막모세포종 치료 시장 보고서 : 유형별, 치료 유형별, 병기별, 용도별, 지역별(2025-2033년)
Retinoblastoma Treatment Market Report by Type, Treatment Type, Type of Staging, Application, and Region 2025-2033
상품코드:1635852
리서치사:IMARC
발행일:2025년 01월
페이지 정보:영문 142 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
망막모세포종 치료 시장 세계 시장 규모는 2024년 30억 달러에 달했습니다. 향후 IMARC Group은 2033년까지 시장 규모가 41억 달러에 달할 것으로 예상하며, 2025-2033년 연평균 성장률(CAGR)은 3.52%에 달할 것으로 전망하고 있습니다. 안과 치료에 대한 의료비 지출의 대폭 증가, 부작용이 적은 치료법 연구 개발(R&D) 활동에 대한 투자 증가, 건강 인식의 증가 등이 시장을 이끄는 주요 요인입니다.
망막모세포종은 가장 흔한 암 중 하나이며, 일반적으로 소아에서는 5세 이전에 발병합니다. 망막모세포종의 증상으로는 고양이 눈 반사(cat's eye reflex) 또는 백반증(leukocoria)이라고 불리는 동공의 혼탁이 있습니다. 망막모세포종 치료에는 다양한 약물전달 및 화학요법이 있으며, 망막모세포종은 초기에는 치료가 가능하기 때문에 단기적으로 일정한 효과를 얻을 수 있으며, 1차 또는 2차 화학요법 후 종양의 축소 정도와 안구 내 위치에 따라 다양한 국소 치료법을 적용할 수 있습니다. 적용할 수 있습니다. 다양한 치료법을 조합하는 것이 가장 성공적인 망막모세포종 치료법입니다. 수술은 망막에서 종양을 완전히 제거하기 때문에 영구적인 망막모세포종 치료법입니다. 망막모세포종의 정밀 진단을 위해 초음파 검사, CT, MRI, X선 검사, 뼈 스캔 등 다양한 영상 검사를 시행할 수 있습니다.
망막모세포종 치료 시장 동향:
안과 치료에 대한 의료비 지출이 크게 증가하면서 시장을 주도하는 중요한 요인으로 작용하고 있습니다. 그 배경에는 젊은 연령층에서 망막모세포종의 증가가 있습니다. 이에 따라 부작용이 적고 효율적인 새로운 치료 전략에 초점을 맞춘 연구 개발(R&D) 활동에 대한 투자가 증가하고 있으며, 이는 시장에 탄력을 주고 있습니다. 또한, 다양한 종류의 암에 대한 인식이 높아지면서 진단율과 치료율이 높아지고 있는 것도 큰 성장 촉진요인으로 작용하고 있습니다. 그러나 다양한 망막모세포종 치료의 미비한 가용성과 엄격한 약사법 규제가 시장 성장의 걸림돌로 작용하고 있습니다. 반면, 신약 출시로 이어지는 제품 승인 건수가 증가하고 있다는 점은 시장 전망을 밝게 하고 있습니다. 이와 더불어, 망막모세포종의 재발률 증가는 망막모세포종 치료 시장에 유리한 기회를 창출하고 있습니다. 또한, 이 시장은 제휴, 공동연구, 인수합병(M&A) 등 주요 지불자가 시행하는 다양한 유기적 성장 전략에 의해 촉진되고 있습니다. 이와는 별도로, 강력한 파이프라인 의약품의 존재와 임상시험의 증가는 시장 성장을 촉진하고 있습니다. 또한, 급속한 도시화, 가처분 소득 수준 증가, 암 연구의 상당한 성장, 전 세계 의료 인프라의 개선 등도 시장 성장에 기여하고 있습니다.
The global retinoblastoma treatment market size reached USD 3.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.1 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033. A considerable rise in healthcare expenditure for ophthalmic treatment procedures, increasing investments in research and development (R&D) activities on therapies with lower side effects, and the increasing health consciousness represent some of the key factors driving the market.
Retinoblastoma is one of the most common cancers that generally develops before the age of 5 in children. Some of the symptoms of retinoblastoma include a white appearance in the pupil called cat's eye reflex or leukocoria. Retinoblastoma treatment can include a variety of drug delivery and chemotherapy techniques that provide some benefits in the short term since retinoblastoma is curable at the initial stage. Following the first or second chemotherapy cycle, different focal treatments can then be applied depending on how much the tumor shrinks and where it is in the eye. A combination of different treatment methods is the most successful retinoblastoma treatment option. Surgery is the permanent retinoblastoma treatment option as it removes the tumor thoroughly from the retina. There are a variety of imaging tests available for a detailed diagnosis of retinoblastoma, including ultrasound, CT-scan, MRI, X-ray, and bone scan.
Retinoblastoma Treatment Market Trends:
A considerable rise in healthcare expenditure for ophthalmic treatment procedures is a significant factor driving the market. This can be attributed to the rising incidences of retinoblastoma among the younger population. In line with this, increasing investments in research and development (R&D) activities focusing on newer, more efficient therapeutic strategies with lesser associated side effects is providing an impetus to the market. Moreover, the growing awareness regarding different type of cancers resulting in higher diagnosis and treatment rates are also acting as a significant growth-inducing factor. However, the lack of availability of various retinoblastoma treatment drugs, along with stringent drug regulations, are acting as a growth-restraining factor for the market. On the contrary, the increasing number of product approvals leading to the launches of new drug variants is creating a positive outlook for the market. Besides this, the growing rates of recurrence of retinoblastoma are also creating lucrative opportunities in the retinoblastoma treatment market. The market is further propelled by various organic growth strategies undertaken by key payers, such as partnerships and collaborations, and merger and acquisitions (M&As). Apart from this, the presence of strong pipeline drugs, along with the augmenting number of clinical trials, are fueling the market growth. Some of the other factors contributing to the market include rapid urbanization, inflating disposable income levels, considerable growth in cancer research, and improvements in medical infrastructure across the globe.
Key Market Segmentation:
Type Insights:
Non-Hereditary Retinoblastoma
Hereditary Retinoblastoma
Treatment Type Insights:
Surgery
Radiation Therapy
Laser Therapy (Photocoagulation)
Cryotherapy
Thermotherapy
Chemotherapy
Opthalmic Artery Infusion Chemotherapy
High-Dose Chemotherapy and Stem Cell Transplant
Type of Staging Insights:
Intraocular Retinoblastoma
Extraocular Retinoblastoma
Application Insights:
Hospitals
Cancer Institutes
Others
Regional Insights:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific was the largest market for retinoblastoma treatment. Some of the factors driving the Asia Pacific retinoblastoma treatment market include the growing rates of recurrence of retinoblastoma, higher diagnosis and treatment rates due to the increasing awareness regarding different types of cancers, the presence of several key players in the region, etc.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global retinoblastoma treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol Myers Squibb Company, Pfizer Inc., Teva Canada Limited (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
How has the global retinoblastoma treatment market performed so far and how will it perform in the coming years ?
What are the drivers, restraints, and opportunities in the global retinoblastoma treatment market ?
What are the key regional markets ?
Which countries represent the most attractive retinoblastoma treatment markets ?
What is the breakup of the market based on the type ?
What is the breakup of the market based on the treatment type ?
What is the breakup of the market based on the type of staging ?
What is the breakup of the market based on application ?
What is the competitive structure of the global retinoblastoma treatment market ?
Who are the key players/companies in the global retinoblastoma treatment market ?
Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Retinoblastoma Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Non-Hereditary Retinoblastoma
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Hereditary Retinoblastoma
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Treatment Type
7.1 Surgery
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Radiation Therapy
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Laser Therapy (Photocoagulation)
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Cryotherapy
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Thermotherapy
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Chemotherapy
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Opthalmic Artery Infusion Chemotherapy
7.7.1 Market Trends
7.7.2 Market Forecast
7.8 High-Dose Chemotherapy and Stem Cell Transplant
